Clinical trials: Urinary Complications
Ureteral Cancer, Urothelial Cancer
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.
- Conditions
- Ureteral Cancer, Urothelial Cancer, Bladder Cancer
- Trial name
- NCT03474107
- Testing
- Enfortumab Vedotin, Docetaxel, Vinflunine
- Where
- 158 sites in United States, Argentina and 17 more
- Volunteers
- 608 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urge Incontinence, Urinary Retention
Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control
The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.
- Trial name
- NCT00225966
- Testing
- Device Medtronic InterStim Tined Leads Models 3889 and 3093
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder.
- Trial name
- NCT00495053
- Testing
- hMaxi-K
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Urovant Sciences GmbH
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Bladder Cancer, Transitional Cell Carcinoma
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin.
- Conditions
- Bladder Cancer, Transitional Cell Carcinoma, Metastasis
- Trial name
- NCT00389155
- Testing
- Vinflunine, Gemcitabine
- Where
- 112 sites in United States, Australia and 14 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Urinary Tract Diseases
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome
The purpose of this study is to determine whether Tamusulosin is effective in the treatment of lower urinary tract syndrome with male patients.
- Trial name
- NCT00239317
- Testing
- Tamusulosin
- Where
- 7 sites in Japan
- Sponsor
- Astellas Pharma Inc
Bladder Cancer
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence.
- Trial name
- NCT05508568
- Testing
- ADXBLADDER
- Where
- 13 sites in United States
- Volunteers
- 650 people
- Sponsor
- Arquer Diagnostics Ltd
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Urinary Incontinence
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
- Trial name
- NCT00139724
- Testing
- tolterodine extended release capsule
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Chronic Glomerulonephritis, Diabetic Nephropathy
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
The treatment period was 16 weeks, the initial dose, 5 mg, was unforcedly titrated to 10 mg, 20 mg and 40 mg after confirming tolerance at weeks 4, 8 and 12.
- Trial name
- NCT00914524
- Testing
- olmesartan medoxomil
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Urinary Incontinence, Stress
Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence
The purposes of this study are to determine whether duloxetine can help subjects with stress urinary incontinence and to see whether the effects of duloxetine can be maintained.
- Trial name
- NCT00190996
- Testing
- Duloxetine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 2,765 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp
Overactive Bladder (OAB)
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
- Trial name
- NCT00507169
- Testing
- SVT-40776
- Sponsor
- Salvat
Urothelial Carcinoma
The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma
The clinical trial was designed to determine the efficacy (sensitivity and specificity) of the IUrisure test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of urothelial…
- Trial name
- NCT06564363
- Testing
- IUrisure test
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Overactive Bladder (OAB)
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.
- Trial name
- NCT03903094
- Testing
- Non-Interventional
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 6,295,279 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Urinary Bladder Neoplasms, Carcinoma in Situ
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC).
- Conditions
- Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT05014139
- Testing
- Enfortumab vedotin
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 37 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Bladder Cancer, Muscle-invasive
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).
- Trial name
- NCT03924895
- Testing
- Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
- Where
- 242 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy.
- Trial name
- VISTA (NCT02449239)
- Testing
- Vicinium
- Where
- 70 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- Sesen Bio, Inc.
Bladder Cancer, Urothelial Carcinoma
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma
- Trial name
- ATLAS (NCT03397394)
- Testing
- Rucaparib
- Where
- 64 sites in United States, France and 4 more
- Volunteers
- 97 people
- Sponsor
- pharmaand GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.